Publications by authors named "Michele Anahory"
Article Synopsis
- BRCA1 and BRCA2 gene mutations play a significant role in hereditary breast cancer and are increasingly important for determining eligibility for PARP inhibitor therapies.
- Updated guidelines for BRCA testing are necessary due to the overlap of genetic testing with both preventive measures and treatment strategies for breast cancer patients.
- An expert international group, including various healthcare professionals, developed recommendations to improve genetic counseling, update testing indications for therapy, and streamline the testing process for managing breast cancer effectively.
In oncology, the expanding use of multi-gene panels to explore familial cancer predisposition and tumor genome analysis has led to increased secondary findings discoveries (SFs) and has given rise to important medical, ethical, and legal issues. The American College of Medical Genetics and Genomics published a policy statement for managing SFs for a list of genes, including 25 cancer-related genes. Currently, there are few recommendations in Europe.
View Article and Find Full Text PDF